A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike

Significance Measles virus (MeV) vaccine is one of the safest and most efficient vaccines with a track record in children. Here, we generated a panel of rMeV-based vaccines with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S antigens inserted near 3′ of the MeV genome. The rMeV expressing a soluble stabilized, prefusion spike (preS) is much more potent in triggering SARS-CoV-2–specific neutralizing antibody than rMeV-based full-length S vaccine candidate. A single dose of rMeV-preS is sufficient to induce high levels of SARS-CoV-2 antibody in animals. Furthermore, rMeV-preS induces high levels of Th1-biased immunity. Hamsters immunized with rMeV-preS were completely protected against SARS-CoV-2 challenge. Our results demonstrate rMeV-preS is a safe and highly efficacious bivalent vaccine candidate for SARS-CoV-2 and MeV. The current pandemic of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights an urgent need to develop a safe, efficacious, and durable vaccine. Using a measles virus (rMeV) vaccine strain as the backbone, we developed a series of recombinant attenuated vaccine candidates expressing various forms of the SARS-CoV-2 spike (S) protein and its receptor binding domain (RBD) and evaluated their efficacy in cotton rat, IFNAR−/−mice, IFNAR−/−-hCD46 mice, and golden Syrian hamsters. We found that rMeV expressing stabilized prefusion S protein (rMeV-preS) was more potent in inducing SARS-CoV-2–specific neutralizing antibodies than rMeV expressing full-length S protein (rMeV-S), while the rMeVs expressing different lengths of RBD (rMeV-RBD) were the least potent. Animals immunized with rMeV-preS produced higher levels of neutralizing antibody than found in convalescent sera from COVID-19 patients and a strong Th1-biased T cell response. The rMeV-preS also provided complete protection of hamsters from challenge with SARS-CoV-2, preventing replication in lungs and nasal turbinates, body weight loss, cytokine storm, and lung pathology. These data demonstrate that rMeV-preS is a safe and highly efficacious vaccine candidate, supporting its further development as a SARS-CoV-2 vaccine.

[1]  R. Baric,et al.  A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine , 2020, Proceedings of the National Academy of Sciences of the United States of America.

[2]  K. L. La Perle,et al.  Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein , 2020, Journal of Virology.

[3]  P. Dormitzer,et al.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.

[4]  F. Krammer.  SARS-CoV-2 vaccines in development , 2020, Nature.

[5]  S. Kent,et al.  Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies , 2020, Nature Microbiology.

[6]  Lisa E. Gralinski,et al.  A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2 , 2020, Cell.

[7]  E. Walsh,et al.  Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults , 2020, Nature.

[8]  Jiyong Zhou,et al.  Porcine Epidemic Diarrhea Virus Deficient in RNA Cap Guanine-N-7 Methylation Is Attenuated and Induces Higher Type I and III Interferon Responses , 2020, Journal of Virology.

[9]  H. Sharpe,et al.  The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world , 2020, Immunology.

[10]  W. Wang,et al.  Viral and host factors related to the clinical outcome of COVID-19 , 2020, Nature.

[11]  P. Hotez,et al.  COVID-19 vaccine design: the Janus face of immune enhancement , 2020, Nature Reviews Immunology.

[12]  P. Hotez,et al.  Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19 , 2020, Human vaccines & immunotherapeutics.

[13]  Zacharias E. Andreadakis,et al.  The COVID-19 vaccine development landscape , 2020, Nature Reviews Drug Discovery.

[14]  L. Saif,et al.  COVID-19 from veterinary medicine and one health perspectives: What animal coronaviruses have taught us , 2020, Research in Veterinary Science.

[15]  D. Griffin,et al.  A durable protective immune response to wild-type measles virus infection of macaques is due to viral replication and spread in lymphoid tissues , 2020, Science Translational Medicine.

[16]  T. Nakayama,et al.  Recombinant Measles AIK-C Vaccine Strain Expressing Influenza HA Protein , 2020, Vaccines.

[17]  K. Shi,et al.  Structural basis of receptor recognition by SARS-CoV-2 , 2020, Nature.

[18]  Shibo Jiang,et al.  Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine , 2020, Cellular & Molecular Immunology.

[19]  T. Palaga,et al.  Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. , 2020, Asian Pacific journal of allergy and immunology.

[20]  Young-Jun Park,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[21]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[22]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[23]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[24]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[25]  A. Tricco,et al.  The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness – A systematic review , 2019, Vaccine.

[26]  J. Mascola,et al.  A proof of concept for structure-based vaccine design targeting RSV in humans , 2019, Science.

[27]  P. Strebel.  Measles , 2019, The New England journal of medicine.

[28]  F. Tangy,et al.  Measles-vectored vaccine approaches against viral infections: a focus on Chikungunya , 2019, Expert review of vaccines.

[29]  C. Walker,et al.  Vaccination to prevent T cell subversion can protect against persistent hepacivirus infection , 2019, Nature Communications.

[30]  E. Reisinger,et al.  Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial , 2018, The Lancet.

[31]  G. Gabriel,et al.  A Measles Virus-Based Vaccine Candidate Mediates Protection against Zika Virus in an Allogeneic Mouse Pregnancy Model , 2018, Journal of Virology.

[32]  M. Beltramello,et al.  Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1–4 , 2018, Proceedings of the National Academy of Sciences.

[33]  F. Tangy,et al.  hCD46 receptor is not required for measles vaccine Schwarz strain replication in vivo: Type-I IFN is the species barrier in mice. , 2018, Virology.

[34]  T. Scott,et al.  Measles vaccine , 2018, Reactions Weekly.

[35]  Shibo Jiang,et al.  Prospects for a MERS-CoV spike vaccine , 2018, Expert review of vaccines.

[36]  Steffen Prüfer,et al.  Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model , 2018, Virology.

[37]  J. Mascola,et al.  HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure. , 2018, Immunity.

[38]  Yao-Wei Huang,et al.  Enhancement of safety and immunogenicity of the Chinese Hu191 measles virus vaccine by alteration of the S-adenosylmethionine (SAM) binding site in the large polymerase protein , 2018, Virology.

[39]  F. Tangy,et al.  Measles-derived vaccines to prevent emerging viral diseases , 2018, Microbes and Infection.

[40]  A. Hinman,et al.  Measles and Rubella Global Strategic Plan 2012-2020 midterm review report: Background and summary. , 2018, Vaccine.

[41]  M. Mühlebach,et al.  Vaccine platform recombinant measles virus , 2017, Virus Genes.

[42]  J. Custers,et al.  Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines. , 2016, The Journal of general virology.

[43]  Krishna Shankara Narayanan,et al.  Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus , 2016, Human vaccines & immunotherapeutics.

[44]  H. Eldin,et al.  A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform , 2015, Journal of Virology.

[45]  N. Escriou,et al.  Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein , 2014, Virology.

[46]  Cinque S. Soto,et al.  Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus , 2013, Science.

[47]  U. Baxa,et al.  Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody , 2013, Science.

[48]  M. Green,et al.  The cotton rat (Sigmodon hispidus) as an animal model for respiratory tract infections with human pathogens , 2013, Lab Animal.

[49]  Cynthia L. de la Fuente,et al.  Broadly Neutralizing Immune Responses against Hepatitis C Virus Induced by Vectored Measles Viruses and a Recombinant Envelope Protein Booster , 2012, Journal of Virology.

[50]  P. Desprès,et al.  Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection. , 2012, The Journal of infectious diseases.

[51]  R. Couch,et al.  Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus , 2012, PloS one.

[52]  H. Ebihara,et al.  Pathogenesis and Host Response in Syrian Hamsters following Intranasal Infection with Andes Virus , 2011, PLoS pathogens.

[53]  Lisa E. Gralinski,et al.  A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge , 2011, Journal of Virology.

[54]  H. Ebihara,et al.  Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus) , 2011, Journal of Immunological Methods.

[55]  D. Kelvin,et al.  Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses , 2008, Vaccine.

[56]  P. Desprès,et al.  Pediatric Measles Vaccine Expressing a Dengue Antigen Induces Durable Serotype-specific Neutralizing Antibodies to Dengue Virus , 2007, PLoS neglected tropical diseases.

[57]  S. Whelan,et al.  A unique strategy for mRNA cap methylation used by vesicular stomatitis virus. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[58]  S. Whelan,et al.  Amino Acid Residues within Conserved Domain VI of the Vesicular Stomatitis Virus Large Polymerase Protein Essential for mRNA Cap Methyltransferase Activity , 2005, Journal of Virology.

[59]  S. Harrison,et al.  Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.

[60]  Jingxin Cao,et al.  Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets , 2005, Vaccine.

[61]  L. Mollet,et al.  A Single Injection of Recombinant Measles Virus Vaccines Expressing Human Immunodeficiency Virus (HIV) Type 1 Clade B Envelope Glycoproteins Induces Neutralizing Antibodies and Cellular Immune Responses to HIV , 2004, Journal of Virology.

[62]  M. Billeter,et al.  Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses. , 2001, Vaccine.

[63]  M. Billeter,et al.  Rescue of measles viruses from cloned DNA. , 1995, The EMBO journal.

[64]  B. Moss,et al.  Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[65]  H. Mirchamsy,et al.  Pathogenesis of vaccine strains of measles virus in suckling hamsters. , 1972, Acta virologica.

[66]  F. Rapp,et al.  Encephalitis in Newborn Hamsters after Intracerebral Injection of Attenuated Human Measles Virus , 1970, Nature.

[67]  S. Niewiesk,et al.  Current animal models: cotton rat animal model. , 2009, Current topics in microbiology and immunology.

[68]  J. Bergh,et al.  BACKGROUND AND SUMMARY , 2006 .

[69]  Jeremy Fairbank,et al.  Historical Perspective , 1987, Do We Really Understand Quantum Mechanics?.